Evidence map›Paper›PMID 39576233›Full record

ReviewAnnals of the New York Academy of Sciences2024

The impact of retrotransposons on zygotic genome activation and the chromatin landscape of early embryos.

Therese Solberg, Mie Kobayashi-Ishihara, Haruhiko Siomi

Abstract readReview
In one paragraph

Review in Annals of the New York Academy of Sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Therese SolbergDepartment of Molecular Biology, Keio University School of Medicine, Tokyo, Japan.
Mie Kobayashi-IshiharaDepartment of Molecular Biology, Keio University School of Medicine, Tokyo, Japan.
Haruhiko SiomiDepartment of Molecular Biology, Keio University School of Medicine, Tokyo, Japan.

Funding

MEXT, JSPS, Takeda Science Foundation, Keio University Academic Funds, Sumitomo Foundation
6 · The paper itself

Abstract

In mammals, fertilization is followed by extensive reprogramming and reorganization of the chromatin accompanying the transcriptional activation of the embryo. This reprogramming results in blastomeres with the ability to give rise to all cell types and a complete organism, including extra-embryonic tissues, and is known as totipotency. Transcriptional activation occurs in a process known as zygotic genome activation (ZGA) and is tightly linked to the expression of transposable elements, including endogenous retroviruses (ERVs) such as endogenous retrovirus with leucine tRNA primer (ERVL). Recent studies discovered the importance of ERVs in this process, yet the race to decipher the network surrounding these elements is still ongoing, and the molecular mechanism behind their involvement remains a mystery. Amid a recent surge of studies reporting the discovery of various factors and pathways involved in the regulation of ERVs, this review provides an overview of the knowns and unknowns in the field, with a particular emphasis on the chromatin landscape and how ERVs shape preimplantation development in mammals. In so doing, we highlight recent discoveries that have advanced our understanding of how these elements are involved in transforming the quiescent zygote into the most powerful cell type in mammals.

Indexed as

ChromatinRetroelementsZygoteAnimalsEmbryo, MammalianEmbryonic DevelopmentEndogenous RetrovirusesGene Expression Regulation, DevelopmentalGenomeHumansTranscriptional ActivationChromatinRetroelementsembryogenesisendogenous retrovirusespluripotencytotipotencytransposable elementszygotic genome activation

Identifiers

PMID39576233
PMCPMC11668504

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.